Profound Medical (TSE:PRN) Trading Up 4.3% – Time to Buy?

Shares of Profound Medical Corp. (TSE:PRN) shot up 4.3% on Tuesday . The stock traded as high as C$9.60 and last traded at C$9.56. 11,300 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 16,826 shares. The stock had previously closed at C$9.17.

Profound Medical Price Performance

The firm has a fifty day moving average of C$9.29 and a two-hundred day moving average of C$9.47. The company has a debt-to-equity ratio of 12.56, a current ratio of 6.56 and a quick ratio of 14.98. The stock has a market capitalization of C$347.39 million, a P/E ratio of -7.71 and a beta of 1.26.

Profound Medical (TSE:PRN) last posted its earnings results on Thursday, May 7th. The company reported C$0.26 earnings per share (EPS) for the quarter. Profound Medical had a negative return on equity of 78.75% and a negative net margin of 206.94%.The company had revenue of C$7.42 million for the quarter. On average, analysts predict that Profound Medical Corp. will post -1.9000001 EPS for the current year.

Insider Transactions at Profound Medical

In related news, Director Dr. Arun Menawat bought 20,000 shares of the business’s stock in a transaction on Friday, March 20th. The shares were bought at an average price of C$6.96 per share, for a total transaction of C$139,200.00. Following the completion of the purchase, the director directly owned 658,660 shares of the company’s stock, valued at approximately C$4,584,273.60. This trade represents a 3.13% increase in their ownership of the stock. 8.62% of the stock is owned by company insiders.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.